Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Current Leases (2021 - 2025)

Avidity Biosciences (RNA) has disclosed Current Leases for 5 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 2.45% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Dec 2025, up 2.45%, and an annual FY2025 reading of $3.9 million, up 2.45% over the prior year.
  • Current Leases was $3.9 million for Q4 2025 at Avidity Biosciences, down from $4.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $4.0 million in Q3 2025 and bottomed at $1.8 million in Q4 2021.
  • Average Current Leases over 5 years is $3.4 million, with a median of $3.6 million recorded in 2023.
  • The sharpest move saw Current Leases skyrocketed 75.52% in 2022, then grew 2.45% in 2025.
  • Year by year, Current Leases stood at $1.8 million in 2021, then surged by 75.52% to $3.1 million in 2022, then rose by 17.2% to $3.6 million in 2023, then rose by 5.63% to $3.8 million in 2024, then increased by 2.45% to $3.9 million in 2025.
  • Business Quant data shows Current Leases for RNA at $3.9 million in Q4 2025, $4.0 million in Q3 2025, and $3.9 million in Q2 2025.